Germ-Line Mutation

"Germ-Line Mutation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.

Descriptor ID	D018095
MeSH Number(s)	G05.365.590.350
Concept/Terms	Germ-Line Mutation Germ-Line Mutation Germ Line Mutation Germline Mutation Germline Mutations Mutation, Germline Mutations, Germline Mutation, Germ-Line Germ-Line Mutations Mutation, Germ Line Mutations, Germ-Line

Below are MeSH descriptors whose meaning is more general than "Germ-Line Mutation".

Biological Sciences [G]
Genetic Phenomena [G05]
Genetic Variation [G05.365]
Mutation [G05.365.590]
Germ-Line Mutation [G05.365.590.350]

Below are MeSH descriptors whose meaning is more specific than "Germ-Line Mutation".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Germ-Line Mutation" by people in this website by year, and whether "Germ-Line Mutation" was a major or minor topic of these publications.

Bar chart showing 149 publications over 30 distinct years, with a maximum of 15 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	1	2
1997	1	0	1
1998	1	1	2
1999	1	2	3
2000	2	1	3
2001	1	1	2
2002	1	1	2
2003	0	1	1
2004	6	1	7
2005	0	1	1
2006	2	2	4
2007	1	1	2
2008	2	1	3
2009	2	0	2
2010	1	2	3
2011	3	4	7
2012	3	5	8
2013	2	1	3
2014	3	1	4
2015	2	0	2
2016	2	8	10
2017	3	5	8
2018	3	4	7
2019	6	1	7
2020	4	11	15
2021	7	6	13
2022	2	2	4
2023	1	7	8
2024	8	5	13
2025	2	0	2

Below are the most recent publications written about "Germ-Line Mutation" by people in Profiles.

Shore N, Armstrong AJ, Barata P, Byrne L, Hafron J, Young S, Paller C, Wise DR, Ventii K, Samadi A, Arangua P, Werahera PN, Lorentz J. Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice. Urology. 2025 05; 199:1-10.

View in: PubMed
Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Feb 20; 43(6):748-758.

View in: PubMed
Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath EI, Helfand BT, Hussain M, Mckay RR, Morgans AK, Morris MJ, Paller CJ, Ross AE, Sartor O, Shen J, Sieber P, Smith MR, Wise DR, Armstrong AJ. Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO Oncol Pract. 2025 Jun; 21(6):747-753.

View in: PubMed
Gallanis AF, Bowden C, Lopez R, Gamble LA, Samaranayake SG, Payne C, Snyder D, Fasaye GA, Joyce S, Broesamle R, Miao N, Miettinen M, Quezado M, Kim SA, Korman L, Heller T, Blakely AM, Hernandez JM, Davis JL. Lessons learned from 150 total gastrectomies for prevention of cancer. J Gastrointest Surg. 2025 Jan; 29(1):101889.

View in: PubMed
Shakroo YM, Seabury CA, Iczkowski KA, Nelson K, Qian J, Ramnani DM. Germline pathogenic variants in prostate cancer. Pathol Res Pract. 2024 Dec; 264:155718.

View in: PubMed
Liss MA, Zeltser N, Zheng Y, Lopez C, Liu M, Patel Y, Yamaguchi TN, Eng SE, Tian M, Semmes OJ, Lin DW, Brooks JD, Wei JT, Klein EA, Tewari AK, Mosquera JM, Khani F, Robinson BD, Aasad M, Troyer DA, Kagan J, Sanda MG, Thompson IM, Boutros PC, Leach RJ. Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. Cancer Epidemiol Biomarkers Prev. 2024 Nov 01; 33(11):1500-1511.

View in: PubMed
Brody JR, Klein AP. The Pivotal Role of Germline BRCA2 Pathogenic Variants in "Apparently Sporadic" Pancreatic Cancer. Cancer Res. 2024 Sep 16; 84(18):2941-2943.

View in: PubMed
Cheng HH, Shevach JW, Castro E, Couch FJ, Domchek SM, Eeles RA, Giri VN, Hall MJ, King MC, Lin DW, Loeb S, Morgan TM, Offit K, Pritchard CC, Schaeffer EM, Szymaniak BM, Vassy JL, Katona BW, Maxwell KN. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review. JAMA Oncol. 2024 Sep 01; 10(9):1272-1281.

View in: PubMed
Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Dato P, Bevan-Thomas R, Wise DR, Hardwick MK, Rojahn S, Layman P, Heald B, Ellsworth RE, Hatchell KE, Nussbaum RL, Nielsen SM, Esplin ED. Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer. J Urol. 2024 Dec; 212(6):832-843.

View in: PubMed
Wood KA, Tong RS, Motta M, Cordeddu V, Scimone ER, Bush SJ, Maxwell DW, Giannoulatou E, Caputo V, Traversa A, Mancini C, Ferrero GB, Benedicenti F, Grammatico P, Melis D, Steindl K, Brunetti-Pierri N, Trevisson E, Wilkie AO, Lin AE, Cormier-Daire V, Twigg SR, Tartaglia M, Goriely A. SMAD4 mutations causing Myhre syndrome are under positive selection in the male germline. Am J Hum Genet. 2024 Sep 05; 111(9):1953-1969.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement